A positive polypeptide pool for tumor vaccine immune response detection and preparation method thereof

Abstract

The invention discloses a positive polypeptide pool for tumor vaccine immune response detection and a preparation method thereof. The positive polypeptide pool is composed of multiple combined peptides prepared from the following polypeptide sequences; The epitope peptide sequence that is efficiently presented and induces an immune response is marked as a segment A sequence; the epitope peptide sequence that can bind to MHC class II molecules and is efficiently presented and causes an immune response is marked as a segment B sequence; by The Linker sequence connects the A-segment sequence and the B-segment sequence to form a complete polypeptide sequence; the positive polypeptide pool prepared by using the present invention can be used as a polypeptide pool for detecting positive control stimuli in vitro for the immune response of polypeptide vaccines, so that the obtained universal positive polypeptide pool It has a mechanism of stimulating the immune system to respond similarly to tumor polypeptide vaccines, avoiding false negatives, and the detection results are highly accurate, stable and reliable.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a positive polypeptide pool for tumor vaccine immune response detection and a preparation method thereof. Background technique [0002] In January 2019, the National Cancer Center released the latest statistical data. In 2015, there were about 3.929 million malignant tumors in my country, and about 2.338 million deaths. On average, more than 10,000 people are diagnosed with cancer every day, and 7.5 people are diagnosed with cancer every minute. Although conquering tumors is the goal that researchers have been pursuing for a long time, there are still huge difficulties. One important reason for this is the widespread tumor heterogeneity. Not only within the tumor tissue, even within the same type of tumor, there are great differences among different patients. Rapidly growing and proliferating cancer cells often have no time to repair the coding errors generated during DNA replicat...

AI Technical Summary

Problems solved by technology

The current positive control, in which CEF can directly combine with MHC to form MHC-antigen complex, only needs the presentation of antigen-presenting cells (APC) (no uptake processing), while PHA, PMA, and Ionomycin all directly stimulate T cells do not require the participation of APC[4], so these positive controls cannot completely simulate the complex process of protein antigens passing through immature DC to mature DC and then presented to T cells

[0004] However, the peptide vaccines currently used in tumor immunotherapy are generally long peptides with a length of 20-35 amino acids. After entering the human body, they need to be ingested, processed, and presented to T cells by APCs before they can produce specific immune responses. Humanized tumor neoantigens have strong complexity from individual to individual

If CEF, PHA or PMA is also used as the positive control product of the tumor peptide vaccine, due to its different mechanism of action from the long peptide, some false negative results may not be ruled out (for example, when the peptide vaccine group is negative, if the CEF and positive peptide If the pools are all negative, it means that the cell itself is abnormal or the experimental process is abnormal; if the CEF is positive and the positive polypeptide pool is negative, it means that the APC cell function is abnormal, which can be determined as a false negative; if both the CEF and the positive polypeptide pool are positive, indicating that the peptide vaccine did not induce an immune response or the immune response was extremely weak), thus reducing the credibility of the experimental results

Images